These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 21168197)

  • 41. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.
    Tol J; Dijkstra JR; Klomp M; Teerenstra S; Dommerholt M; Vink-Börger ME; van Cleef PH; van Krieken JH; Punt CJ; Nagtegaal ID
    Eur J Cancer; 2010 Jul; 46(11):1997-2009. PubMed ID: 20413299
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Nras and Kras mutation in Japanese lung cancer patients: Genotyping analysis using LightCycler.
    Sasaki H; Okuda K; Kawano O; Endo K; Yukiue H; Yokoyama T; Yano M; Fujii Y
    Oncol Rep; 2007 Sep; 18(3):623-8. PubMed ID: 17671710
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations.
    Zimmer L; Barlesi F; Martinez-Garcia M; Dieras V; Schellens JH; Spano JP; Middleton MR; Calvo E; Paz-Ares L; Larkin J; Pacey S; Venturi M; Kraeber-Bodéré F; Tessier JJ; Eberhardt WE; Paques M; Guarin E; Meresse V; Soria JC
    Clin Cancer Res; 2014 Aug; 20(16):4251-61. PubMed ID: 24947927
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Molecular alterations of PIK3CA in uterine carcinosarcoma, clear cell, and serous tumors.
    Bashir S; Jiang G; Joshi A; Miller C; Matrai C; Yemelyanova A; Caputo TA; Holcomb KM; Ellenson LH; Gupta D
    Int J Gynecol Cancer; 2014 Sep; 24(7):1262-7. PubMed ID: 25078343
    [TBL] [Abstract][Full Text] [Related]  

  • 45. In-depth molecular profiling of the biphasic components of uterine carcinosarcomas.
    McConechy MK; Hoang LN; Chui MH; Senz J; Yang W; Rozenberg N; Mackenzie R; McAlpine JN; Huntsman DG; Clarke BA; Gilks CB; Lee CH
    J Pathol Clin Res; 2015 Jul; 1(3):173-85. PubMed ID: 27499902
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Genomic and Molecular Abnormalities in Gynecologic Clear Cell Carcinoma.
    Marks EI; Brown VS; Dizon DS
    Am J Clin Oncol; 2020 Feb; 43(2):139-145. PubMed ID: 31764020
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Carcinosarcomas of the uterus: molecular-genetic and morphological features].
    Levitskaia NV; Pozharisskiĭ KM; Vostriukhina OA; Alekseeva LN; Nemtsova MV; Matrosova IV; Kharitonova TV; Poddubnaia IV
    Arkh Patol; 2012; 74(1):7-11. PubMed ID: 22712296
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Genomic analyses of gynaecologic carcinosarcomas reveal frequent mutations in chromatin remodelling genes.
    Jones S; Stransky N; McCord CL; Cerami E; Lagowski J; Kelly D; Angiuoli SV; Sausen M; Kann L; Shukla M; Makar R; Wood LD; Diaz LA; Lengauer C; Velculescu VE
    Nat Commun; 2014 Sep; 5():5006. PubMed ID: 25233892
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mutation profiling in gallbladder cancer in Indian population.
    Kumari N; Corless CL; Warrick A; Beadling C; Nelson D; Neff T; Krishnani N; Kapoor VK
    Indian J Pathol Microbiol; 2014; 57(1):9-12. PubMed ID: 24739824
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Integrated Molecular Characterization of Uterine Carcinosarcoma.
    Cherniack AD; Shen H; Walter V; Stewart C; Murray BA; Bowlby R; Hu X; Ling S; Soslow RA; Broaddus RR; Zuna RE; Robertson G; Laird PW; Kucherlapati R; Mills GB; ; Weinstein JN; Zhang J; Akbani R; Levine DA
    Cancer Cell; 2017 Mar; 31(3):411-423. PubMed ID: 28292439
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mutational profiling of the RAS, PI3K, MET and b-catenin pathways in cancer of unknown primary: a retrospective study of the Hellenic Cooperative Oncology Group.
    Pentheroudakis G; Kotteas EA; Kotoula V; Papadopoulou K; Charalambous E; Cervantes A; Ciuleanu T; Fountzilas G; Pavlidis N
    Clin Exp Metastasis; 2014 Oct; 31(7):761-9. PubMed ID: 24997156
    [TBL] [Abstract][Full Text] [Related]  

  • 52. High-throughput mutation profiling of primary and metastatic endometrial cancers identifies KRAS, FGFR2 and PIK3CA to be frequently mutated.
    Krakstad C; Birkeland E; Seidel D; Kusonmano K; Petersen K; Mjøs S; Hoivik EA; Wik E; Halle MK; Øyan AM; Kalland KH; Werner HM; Trovik J; Salvesen H
    PLoS One; 2012; 7(12):e52795. PubMed ID: 23300780
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Gynecologic melanomas: A clinicopathologic and molecular analysis.
    Udager AM; Frisch NK; Hong LJ; Stasenko M; Johnston CM; Liu JR; Chan MP; Harms PW; Fullen DR; Orsini A; Thomas DG; Lowe L; Patel RM
    Gynecol Oncol; 2017 Nov; 147(2):351-357. PubMed ID: 28844540
    [TBL] [Abstract][Full Text] [Related]  

  • 54. p53 and K-ras mutational genotyping in pulmonary carcinosarcoma, spindle cell carcinoma, and pulmonary blastoma: implications for histogenesis.
    Holst VA; Finkelstein S; Colby TV; Myers JL; Yousem SA
    Am J Surg Pathol; 1997 Jul; 21(7):801-11. PubMed ID: 9236836
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Molecular variations in uterine carcinosarcomas identify therapeutic opportunities.
    Crane E; Naumann W; Tait D; Higgins R; Herzog T; Brown J
    Int J Gynecol Cancer; 2020 Apr; 30(4):480-484. PubMed ID: 32114514
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The FOXA2 transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomas.
    Le Gallo M; Rudd ML; Urick ME; Hansen NF; ; Merino MJ; Mutch DG; Goodfellow PJ; Mullikin JC; Bell DW
    Cancer; 2018 Jan; 124(1):65-73. PubMed ID: 28940304
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients.
    Berg A; Hoivik EA; Mjøs S; Holst F; Werner HM; Tangen IL; Taylor-Weiner A; Gibson WJ; Kusonmano K; Wik E; Trovik J; Halle MK; Øyan AM; Kalland KH; Cherniack AD; Beroukhim R; Stefansson I; Mills GB; Krakstad C; Salvesen HB
    Oncotarget; 2015 Jan; 6(2):1327-39. PubMed ID: 25415225
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinicopathological and molecular analyses of uterine carcinosarcomas using next-generation sequencing: A single-center experience.
    Erdogan EG; Yalta TD; Can N; Süt N; Taştekin E; Usta U; Puyan FÖ; Usturalı Keskin FE; Kurt BB
    Indian J Pathol Microbiol; 2023; 66(3):449-455. PubMed ID: 37530323
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Activated Kras, but not Hras or Nras, may initiate tumors of endodermal origin via stem cell expansion.
    Quinlan MP; Quatela SE; Philips MR; Settleman J
    Mol Cell Biol; 2008 Apr; 28(8):2659-74. PubMed ID: 18268007
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Carcinosarcomas and Related Cancers: Tumors Caught in the Act of Epithelial-Mesenchymal Transition.
    Pang A; Carbini M; Moreira AL; Maki RG
    J Clin Oncol; 2018 Jan; 36(2):210-216. PubMed ID: 29220296
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.